Broadcom (AVGO) call put ratio 1.4 calls to 1 put with a focus on August 290 and September 310 calls into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Broadcom Limited (AVGO) PT Raised to $295 at Truist Securities, 'Buy the near-term weakness'
June 6, 2025 7:06 AM EDTTruist Securities analyst William Stein raised the price target on Broadcom Limited (NASDAQ: AVGO) to $295.00 (from $267.00) while maintaining a Buy rating.
The analyst comments "Buy the near-term weakness. AVGO posted very modest upside to CQ1 (Apr) results, and CQ2 (July) guidance.... More
Broadcom Limited (AVGO) PT Raised to $325 at JPMorgan
June 6, 2025 5:16 AM EDTJPMorgan analyst Harlan Sur raised the price target on Broadcom Limited (NASDAQ: AVGO) to $325.00 (from $250.00) while maintaining a Overweight rating.
The analyst comments "We see the recent ruling from the U.S. District Court for the District of Delaware in favor of ACAD regarding its 721 formulation patent for Nuplazid (pimavanserin) on both infringement and validity arguments against Aurobindo Pharma and other ANDA filers (see document here) as a clear positive. Note that the 721 patent provides protection for the Nuplazid 34mg capsule formulation into 2038. We believe it is logical to assume the parties... More
Broadcom Limited (AVGO) PT Raised to $304 at Evercore ISI, 'We’re Still Buyers'
June 6, 2025 4:54 AM EDTEvercore ISI analyst Mark Lipacis raised the price target on Broadcom Limited (NASDAQ: AVGO) to $304.00 (from $267.00) while maintaining a Outperform rating.
The analyst comments "Were Still Buyers of AVGO after an in-line AprQ print and implied EPS outlook that is $0.01 below consensus. AI revs... More
Broadcom Limited (AVGO) PT Raised to $315 at KeyBanc
June 6, 2025 4:49 AM EDTKeyBanc analyst John Vinh raised the price target on Broadcom Limited (NASDAQ: AVGO) to $315.00 (from $275.00) while maintaining a Overweight rating.
The analyst comments "AVGO reported solid F2Q (Apr) results and provided mixed F3Q (Jul) guidance (higher revs, lower... More
Erste Group Upgrades Broadcom Limited (AVGO) to Buy
June 5, 2025 4:58 AM EDTErste Group analyst Hans Engel upgraded Broadcom Limited (NASDAQ: AVGO) from Hold to Buy.
The analyst comments "Broadcom has an attractive product portfolio for network applications, especially software in the field of virtualization with good growth prospects. The operating margin and return... More
